<DOC>
	<DOC>NCT01560637</DOC>
	<brief_summary>This study is an international, multi-center, open-label study designed to provide oral treprostinil (UT-15C) to eligible subjects with pulmonary arterial hypertension who have completed the TDE-PH-310 study. The purpose of this study is to assess the long-term safety of UT-15C and to assess the effects of long-term treatment with UT-15C on exercise capacity.</brief_summary>
	<brief_title>An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Participated in United Therapeutics Study TDEPH310 Premature discontinuation of United Therapeutics Study TDEPH310 due to reasons other than clinical worsening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>PAH</keyword>
	<keyword>PH</keyword>
	<keyword>FREEDOM</keyword>
	<keyword>6 minute walk test</keyword>
	<keyword>treprostinil</keyword>
	<keyword>open label</keyword>
</DOC>